Lung tumors arise from tissues lining the lung and bronchial passages. While cigarette smoking is best known as a cause of lung cancer, the disease can also arise in people who have never smoked. Cases of lung cancer have declined over the last few decades. However, the disease remains the most common cause of cancer-related deaths in the U.S.
There are two main types of lung cancer, small-cell lung cancer and non-small-cell lung cancer. Non-small-cell lung cancers are most common, making up about 85 percent of cases. Squamous cell carcinoma, adenocarcinoma and large-cell carcinoma are all varieties of non-small-cell lung cancer. Small-cell lung cancer, the more aggressive type, makes up about 15 percent of lung cancer cases. About 5 percent of lung tumors are lung carcinoid tumors, a rare and usually slow-growing form of the disease.
Our scientists study the genetic alterations that drive lung cancer development and the factors that shape lung cancer risk. They also study how the constellation of noncancerous cells surrounding the tumor may influence its progression. Our researchers seek to develop improved therapies for this disease and run clinical trials aimed at improving treatment.
Lung cancer research at Fred Hutch spans fundamental studies of the gene changes that drive the disease and large-scale population studies that seek to understand why it develops in some people but not others.
Understanding the inner workings of cancer cells can help researchers discover new drug targets. Our scientists work to pinpoint the critical genetic changes that promote lung cancer and translate these insights into targeted therapies for patients’ individual tumors.
Cancer cells are surrounded by noncancerous cells. Many of these can influence tumor cells’ growth, invasiveness and ability to metastasize, or leave the original tumor and initiate new tumors elsewhere. Our investigators study these nontumor cells and how they interact with lung tumor cells. In particular, Our scientists focus on cells from the immune system. Insights from these studies could point to new therapeutic targets or ways to harness the immune system itself to target lung cancer. Our scientists also carry out clinical trials of immunotherapy strategies against lung cancer.
Though smoking is perhaps the most well-known risk factor for lung cancer, not everyone who smokes will develop lung cancer. And people who have never smoked make up a growing percentage of those diagnosed with lung cancer. Our scientists study the differences in lung tumors in these two populations to seek unique drug targets in each type of tumor. We also perform large-scale population-based studies to better understand why smoking predisposes only some people to lung cancer. Such studies could improve our understanding of who is most at risk of lung cancer and help doctors improve screening strategies.
Researchers tested the efficacy and safety of beta-carotene and retinyl palmitate in people at high risk for lung cancer in a randomized, double-blind, placebo-controlled trial. Active follow-up of trial. participants ended on June of 2005; however, the program continues to support the extensive biological repository and ancillary studies that use CARET samples and data.
Contact: Jackie Dahlgren, email@example.com
Scientists are analyzing the relationship between a body’s ability to repair of smoking-induced DNA damage and the occurrences of lung cancer.
Funding Agency: National Cancer Institute
Contact: Chu Chen, firstname.lastname@example.org
Building on the success of PROSPR I, PROSPR II investigators from a variety of disciplines are conducting research based on cervical, colorectal, and lung cancer screening.
Funding Agency: National Cancer Institute
Contact: Marty Stiller, email@example.com
The VITAL study investigates the associations of supplement use with cancer risk. Investigators are specifically concerned with how vitamin C, E, calcium, multivitamins, folate, omega-3 fatty acids, and fiber related to prostate, breast, lung, colorectal, melanoma, bladder, blood/lymph cancers, as well as total cancer incidence and total mortality.
Funding Agency: National Institutes of Health
Contact: Emily White, firstname.lastname@example.org
Fred Hutch's Lung Specialized Project of Research Excellence (SPORE) is leveraging the strengths of investigators to fast-track the latest breakthroughs for patients and people at risk of developing lung cancer.
Clinical research is an essential part of the scientific process that leads to new treatments and better care. Clinical trials can also be a way for patients to get early access to new cutting-edge therapies. Our clinical research teams are running clinical studies various kinds of lung cancers.
Lung cancer can be caused by a number of factors, including smoking, genetic mutations and exposure to environmental carcinogens. But many people perceive it to be a self-inflicted disease, and the resulting social stigma can lead to delayed diagnosis as well as a dearth of funding for lung cancer research. Patients with lung cancer describe the reactions to their diagnosis.